Given the rescue effects of TR on imbalanced mitochondrial dynamic and apoptosis damage processes in vitro, we intended to subsequently validate the effects of PPARγ agonists on renal damage in calcium oxalate nephrolithiasis within the experimental animal model. The gene discussed is PPARG; the disease is nephrolithiasis susceptibility caused by SLC26A1.